Biogen Inc. (BIIB): Price and Financial Metrics


Biogen Inc. (BIIB): $211.93

0.55 (+0.26%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add BIIB to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

BIIB POWR Grades


  • Value is the dimension where BIIB ranks best; there it ranks ahead of 99.35% of US stocks.
  • BIIB's strongest trending metric is Stability; it's been moving down over the last 179 days.
  • BIIB ranks lowest in Momentum; there it ranks in the 12th percentile.

BIIB Stock Summary

  • With a market capitalization of $31,589,652,355, Biogen Inc has a greater market value than 91.16% of US stocks.
  • Biogen Inc's stock had its IPO on September 17, 1991, making it an older stock than 83.11% of US equities in our set.
  • Revenue growth over the past 12 months for Biogen Inc comes in at -18.32%, a number that bests only 7.75% of the US stocks we're tracking.
  • Stocks that are quantitatively similar to BIIB, based on their financial statements, market capitalization, and price volatility, are KEYS, AEIS, TER, ZBRA, and NAVB.
  • Visit BIIB's SEC page to see the company's official filings. To visit the company's web site, go to www.biogen.com.

BIIB Valuation Summary

  • BIIB's price/earnings ratio is 26.3; this is 27.95% lower than that of the median Healthcare stock.
  • BIIB's EV/EBIT ratio has moved down 38.1 over the prior 243 months.
  • Over the past 243 months, BIIB's price/sales ratio has gone down 36.1.

Below are key valuation metrics over time for BIIB.

Stock Date P/S P/B P/E EV/EBIT
BIIB 2021-08-31 4.3 4.7 26.3 31.2
BIIB 2021-08-30 4.4 4.8 26.8 31.7
BIIB 2021-08-27 4.4 4.8 26.7 31.6
BIIB 2021-08-26 4.4 4.7 26.6 31.5
BIIB 2021-08-25 4.4 4.8 26.6 31.5
BIIB 2021-08-24 4.5 4.8 27.1 32.1

BIIB Growth Metrics

    Its 5 year revenue growth rate is now at 31.88%.
  • Its 5 year cash and equivalents growth rate is now at 129.18%.
  • Its 5 year net income to common stockholders growth rate is now at 59.09%.
BIIB's revenue has moved up $46,063,000 over the prior 70 months.

The table below shows BIIB's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 10,981.7 3,639.9 1,556.1
2021-09-30 11,100.5 2,434.5 1,545.8
2021-06-30 11,697.7 2,810.3 1,918.1
2021-03-31 12,604.3 3,531.5 3,011.7
2020-12-31 13,444.6 4,229.8 4,000.6
2020-09-30 14,263.3 6,557.1 5,082.4

BIIB's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • BIIB has a Quality Grade of B, ranking ahead of 87.69% of graded US stocks.
  • BIIB's asset turnover comes in at 0.459 -- ranking 97th of 680 Pharmaceutical Products stocks.
  • ZSAN, ARMP, and HGEN are the stocks whose asset turnover ratios are most correlated with BIIB.

The table below shows BIIB's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.459 0.825 0.064
2021-06-30 0.478 0.839 0.098
2021-03-31 0.510 0.855 0.206
2020-12-31 0.531 0.866 0.283
2020-09-30 0.550 0.876 0.369
2020-06-30 0.545 0.880 0.415

BIIB Price Target

For more insight on analysts targets of BIIB, see our BIIB price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $417.00 Average Broker Recommendation 1.64 (Moderate Buy)

BIIB Stock Price Chart Interactive Chart >

Price chart for BIIB

BIIB Price/Volume Stats

Current price $211.93 52-week high $372.11
Prev. close $211.38 52-week low $187.16
Day low $207.19 Volume 2,947,000
Day high $212.71 Avg. volume 1,257,333
50-day MA $203.29 Dividend yield N/A
200-day MA $232.46 Market Cap 31.04B

Biogen Inc. (BIIB) Company Bio


Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, specializing in the discovery, development, and delivery of therapies for the treatment of neurological diseases to patients worldwide.(Source:Wikipedia)


BIIB Latest News Stream


Event/Time News Detail
Loading, please wait...

BIIB Latest Social Stream


Loading social stream, please wait...

View Full BIIB Social Stream

Latest BIIB News From Around the Web

Below are the latest news stories about Biogen Inc that investors may wish to consider to help them evaluate BIIB as an investment opportunity.

Ionis (IONS) Q4 Earnings & Revenues Beat Estimates, Stock Up

Teaser: Ionis (IONS) beats Q4 earnings and sales estimates. Stock rises.

Yahoo | February 25, 2022

Medicare’s finances and the saga of the Alzheimer’s drug Aduhelm

The topic is much more exciting — and frightening —  in the wake of Aduhelm, a drug developed by Biogen (BIIB) to treat early-stage Alzheimer’s disease with an original ask price of $56,000 per patient per year. Traditional Medicare is composed of two programs (see Table 1).

Yahoo | February 24, 2022

The Zacks Analyst Blog Highlights Regeneron Pharmaceuticals, Sage Therapeutics, Biogen Agios Pharmaceuticals Atara Biotherapeutics

Regeneron Pharmaceuticals, Sage Therapeutics, Biogen Agios Pharmaceuticals Atara Biotherapeutics are included in this blog.

Yahoo | February 24, 2022

What Investors Can Learn From Biogen''s Drug Approval That No One Wants

Will Aduhelm''s controversial approval signal a new normal for clinical trials?

The Motley Fool | February 23, 2022

The Law Offices of Vincent Wong Remind Biogen Investors of a Lead Plaintiff Deadline of April 8, 2022

The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors who purchased between June 7, 2021 and January 11, 2022. If you suffered a loss on your investment in Biogen, contact us about potential recovery by using []

iCrowdNewswire | February 23, 2022

Read More 'BIIB' Stories Here

BIIB Price Returns

1-mo 3.78%
3-mo 0.46%
6-mo -9.51%
1-year -39.09%
3-year -10.98%
5-year -24.26%
YTD -11.67%
2021 -2.02%
2020 -17.48%
2019 -1.39%
2018 -5.54%
2017 21.96%

Continue Researching BIIB

Want to see what other sources are saying about Biogen Inc's financials and stock price? Try the links below:

Biogen Inc (BIIB) Stock Price | Nasdaq
Biogen Inc (BIIB) Stock Quote, History and News - Yahoo Finance
Biogen Inc (BIIB) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7962 seconds.